GoodRx to Offer Employer Access to Lilly's Zepbound at $449 Monthly Price
By Connor Hart
GoodRx Holdings will offer employers access to Eli Lilly's Zepbound through a new program designed to help companies manage the cost of weight-loss drugs.
The prescription-drug provider said Friday that employers participating in its "Employer Direct" platform will be able to provide workers with the Zepbound KwikPen at a set price of $449 per month across all doses. Employers can choose to further subsidize part of that cost.
The offering underscores GoodRx's ability to connect manufacturer pricing and employer contributions under a single infrastructure, said Laura Jensen, chief commercial officer and president of pharma direct.
GoodRx's Employer Direct platform enables employers to support access to Zepbound KwikPen without altering their core health benefit structure, the company said. The program is designed to complement--but not replace--traditional health plans, it added.
Demand for GLP-1 drugs has surged in recent years, prompting employers and insurers to seek lower-cost options as many health plans have limited or excluded coverage for the treatments.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 06, 2026 09:50 ET (14:50 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States